GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Return-on-Tangible-Equity

AlloVir (AlloVir) Return-on-Tangible-Equity : -91.05% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is AlloVir Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AlloVir's annualized net income for the quarter that ended in Mar. 2024 was $-121.20 Mil. AlloVir's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $133.11 Mil. Therefore, AlloVir's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -91.05%.

The historical rank and industry rank for AlloVir's Return-on-Tangible-Equity or its related term are showing as below:

ALVR' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -102.85   Med: -67.25   Max: -46.28
Current: -101.52

During the past 6 years, AlloVir's highest Return-on-Tangible-Equity was -46.28%. The lowest was -102.85%. And the median was -67.25%.

ALVR's Return-on-Tangible-Equity is ranked worse than
71.67% of 1306 companies
in the Biotechnology industry
Industry Median: -46.43 vs ALVR: -101.52

AlloVir Return-on-Tangible-Equity Historical Data

The historical data trend for AlloVir's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlloVir Return-on-Tangible-Equity Chart

AlloVir Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial - -46.28 -59.47 -75.02 -102.85

AlloVir Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.81 -85.68 -83.44 -140.00 -91.05

Competitive Comparison of AlloVir's Return-on-Tangible-Equity

For the Biotechnology subindustry, AlloVir's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AlloVir's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlloVir's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where AlloVir's Return-on-Tangible-Equity falls into.



AlloVir Return-on-Tangible-Equity Calculation

AlloVir's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-190.418/( (224.519+145.781 )/ 2 )
=-190.418/185.15
=-102.85 %

AlloVir's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-121.196/( (145.781+120.44)/ 2 )
=-121.196/133.1105
=-91.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


AlloVir  (NAS:ALVR) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


AlloVir Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of AlloVir's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


AlloVir (AlloVir) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1100 Winter Street, Waltham, MA, USA, 02451
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Executives
Vikas Sinha director, 10 percent owner, officer: See Remarks C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Edward Miller officer: General Counsel C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen officer: Chief Accounting Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams director ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B officer: Chief Commercial Officer C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy officer: See Remarks C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal director, 10 percent owner, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc director, 10 percent owner C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2 director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd director, 10 percent owner C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018

AlloVir (AlloVir) Headlines

From GuruFocus

AlloVir to Participate in the SVB Securities Global Biopharma Conference

By Business Wire Business Wire 02-01-2023

AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook

By Business Wire Business Wire 02-15-2023